The FDA has issued a statement about the availability of immunoglobulin products, which many myositis patients depend upon for treatment of their disease. The statement says, in part: ” In the setting of the increased demand for Ig, other factors that ordinarily might not impact availability may have a greater effect. These could include uneven…
Continue Reading
Polymyositis, dermatomyositis, and necrotizing myopathy are diseases that are often treated with immunoglobulin (Ig) products, either intravenously (IV) or subcutaneously (SC). Many TMA members find IVIg or SCIg to be a very effective treatment. Recently, however, TMA has become aware of shortages of Ig products in some areas of the country. IVIg and SCIg are…
Continue Reading
A recent article in the journal Current Opinions in Rheumatology discusses significant points related to our current understanding about IBM diagnosis and potential treatments.
Continue Reading